v3.3.0.814

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Aug. 31, 2015	Aug. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (352,219)	$ (39,088)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	257
Derivative expense	105,739
Amortization of debt discount	23,760
Change in fair market value of derivative liability	(48,754)
Amortization of consulting fees	42,944
Changes in operating assets and liabilities:
Decrease in inventory	11,598	$ (12,668)
Decrease (increase) in accounts receivable	25,694	$ (11,497)
Decrease in advances to vendors	2,738
Increase (decrease) in accounts payable and accrued liabilities	34,061	$ (1,120)
Net cash used in operating activities	(154,180)	$ (64,373)
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment acquisitions	(800)
Cash used in investing activities	(800)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the sale of convertible notes payable	165,000
Proceeds from (repayment of) notes payable	16,285	$ (600)
Proceeds from (repayment of) of loans payables	(6,365)	2,907
Proceeds from related party payable	22,419	60,595
Net cash provided by financing activities	197,339	62,902
Net increase (decrease) in cash and cash equivalents	42,359	(1,471)
Cash and cash equivalents, beginning of period	145	4,905
Cash and cash equivalents, end of period	42,504	3,434
Supplemental disclosure of cash flow information:
Interest paid	$ 7,048	$ 2,168
Income taxes paid

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

KollagenX Corp. 10-Q